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Abstract
Background: Repetitive transcranial magnetic stimulation (rTMS) has been investigated as a new tool in neurological
rehabilitation of individuals with spinal cord injury (SCI). However, due to the inconsistent results regarding the effects
of rTMS in people with SCI, a randomized controlled double-blind crossover trial is needed to clarify the clinical utility
and to assess the effect size of rTMS intervention in this population. Therefore, this paper describes a study protocol
designed to investigate whether the use of rTMS can improve the motor and sensory function, as well as reduce
spasticity in patients with incomplete SCI.
Methods: A double-blind randomized sham-controlled crossover trial will be performed by enrolling 20 individuals
with incomplete SCI. Patients who are at least six months post incomplete SCI (aged 18–60 years) will be recruited
through referral by medical practitioners or therapists. Individuals will be randomly assigned to either group 1 or group
2 in a 1:1 ratio, with ten individuals in each group. The rTMS protocol will include ten sessions of high-frequency rTMS
(5 Hz) over the bilateral lower-limb motor area positioned at the vertex (Cz). Clinical evaluations will be performed at
baseline and after rTMS active and sham.
Discussion: rTMS has produced positive results in treating individuals with physical impairments; thus, it might be
promising in the SCI population. The results of this study may provide new insights to motor rehabilitation thereby
contributing towards the better usage of rTMS in the SCI population.
Trial registration: ClinicalTrials.gov, NCT02899637. Registered on 25 August 2016.
Keywords: Incomplete spinal cord injury, Plasticity, Motor rehabilitation, Non-invasive brain stimulation, Repetitive
transcranial magnetic stimulation
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Background
Spinal cord injury (SCI) affects about 2.5 million individ-
uals worldwide and often leads to severe disability, due
to functional limitations in the sensory and motor sys-
tems [1]. After trauma or pathological processes upon
the spinal cord, there is usually some preservation of
sensation, or motor function at the lowest segment of
the spinal cord, a condition known as incomplete SCI
(iSCI) [2]. iSCI has been associated with a serious reduc-
tion in quality of life and functional independence [3, 4].
Therefore, effective rehabilitation programs are required
for patients with iSCI in both acute and chronic care.
Processes of neural regeneration and plasticity can
result in significant functional recovery after iSCI [5].
Spontaneous recovery of motor and sensory function in
iSCI individuals can be substantial, but highly variable
[6]. Repetitive transcranial magnetic stimulation (rTMS)
rehabilitation techniques, based on protocols that select-
ively stimulate specific pathways along the central ner-
vous system (CNS), have been found to be effective in
enhancing neurological recovery leading to improved
functional abilities [7]. rTMS is a procedure that involves
repetitively delivering biphasic magnetic pulses over a
specific cortical site [8, 9] to provide stimulation of the
corticospinal tract (CST), primary motor cortex (M1),
and spinal cord, so as to induce neuronal reorganization,
which can be largely involved in the control of voluntary
movements [10].
Protocols involving rTMS have been used to induce
changes in the excitability of neuronal circuits with posi-
tive effects [11–16] at the site of stimulation or transsynap-
tically at distant sites such as spinal cord circuits [17, 18].
The effect of high-frequency rTMS (i.e. ≥ 5Hz) includes
changes in synaptic plasticity resembling long-term
potentiation (LTP), as well as shifts in network excit-
ability, activation of feedback loops, and activity-
dependent metaplasticity [19, 20]. On this basis, rTMS
is emerging as a promising technique in improving
neurophysiological outcomes and voluntary motor out-
put in patients with motor disorders [11, 21, 22].
Indeed, studies indicate that motor improvements may
be due to modification of corticospinal projections by
increasing motor cortical excitability [14–16] and, con-
sequently, promote plasticity associated with functional
recovery [22]. Additionally, reduction in spasticity may
occur through enhancement of descending corticosp-
inal projections and segmental effects on spinal inter-
neurons that might strengthen inhibitory connections
[13, 14, 23].
Many studies have used rTMS as a non-invasive and
painless method to induce long-lasting changes in the
excitability of cortical and corticospinal pathways after
iSCI. In this scenario, rTMS has been found effective in
enhancing corticospinal synaptic transmission [12],
reducing spasticity [13, 14, 23] and improving sensori-
motor function after iSCI [14–16], although we note
none of these studies reported associated effect sizes in
their analyses. However, other studies report less positive
findings, including unchanged sensorimotor function
[24], as well as unaltered cortical excitability and level of
spasticity [16] in response to rTMS. The lack of consist-
ent results is likely associated with differences in stimu-
lation parameters (e.g. intensity, frequency, number of
pulses), number of sessions, relative location of M1,
chronicity and levels of injury, and outcome measure-
ments used in previous studies [10].
In considering three particular studies that have exam-
ined the effects of rTMS in individuals with iSCI, we note
interesting results on sensory and motor performance.
Belci et al. [15] delivered double pulses of rTMS over the
M1 representation of thenar muscles (360 doublets, sepa-
rated by 100 ms). They used a low frequency (with 10 s
between each doublet and stimulus intensity correspond-
ing to 90% of resting motor threshold [RMT]) for five days
in a group of four individuals with iSCI. Results indicated
that active rTMS improved somatosensory and motor
function at three weeks following stimulation, as assessed
by the American Spinal Injury Association Impairment
Scale (ASIA) nine-hole peg test and electrical perceptual
threshold measurements. Additionally, Benito et al. [14]
applied 15 sessions of sham or rTMS over the leg repre-
sentation of M1 (20 trains of 40 pulses at 20 Hz with an
intensity of 90% of RMT) in 17 individuals with iSCI. This
study found significant improvements in motor function
for at least two weeks, as assessed by the ASIA scale for
lower limbs and gait function. Contrary to the findings
noted above, ASIA scores were unaltered in Kuppuswamy
et al. [24]. The protocol had five days of active or sham
rTMS (900 pulses at 5 Hz in 2 s trains separated by 80-s
intervals, at 80% of active motor threshold) applied to M1
representations of either the hand or forearm muscles in
15 individuals with iSCI. It is worth noting that the studies
cited above have reported sham placebo-controlled trials
which were single-blinded [15, 24], non-randomized [15],
and either all [15, 24], or at least part of the individuals
crossed over between groups during the study [14].
Therefore, while there is good evidence for its use in
other diseases, the literature regarding the efficacy of
rTMS in individuals with iSCI is inconsistent, as the few
studies that have addressed this issue yielded contrasting
results. Due to the quality of the study design as well as
to the differences in rTMS parameters used in previous
studies, there is no strong evidence of consistent
changes in sensory and motor function in individuals
with iSCI after rTMS [10]. Thus, there are gaps in the
knowledge base and hence the development of a new
prospective study, with a fully randomized double-blind
placebo-controlled design [25], is necessary to provide
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evidence of the clinical utility of rTMS in individuals
with iSCI. Due to the positive effects of rTMS in indu-
cing long-lasting changes in spinal and supraspinal cir-
cuits, we hypothesized that rTMS applied over the
lower-limb motor area will: (1) improve motor function;
(2) improve sensory function; and (3) reduce spasticity.
Therefore, our aim was to identify a protocol for a
double-blind randomized controlled crossover trial that
will be performed to evaluate the effects of high-
frequency rTMS on the sensorimotor function and spas-
ticity in individuals with iSCI.
Methods/Design
We registered this trial on ClinicalTrials.gov
(NCT02899637). This paper has been reported in ac-
cordance with the Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT) [26].
Study design
A double-blinded randomized controlled crossover trial
will be conducted and all participants will undertake
rTMS-active and sham. Group 1 will start with five ses-
sions of rTMS-active. After two weeks, this group will
be reallocated to five sessions with rTMS-sham. In con-
trast, group 2 will do the opposite protocol (participants
will start allocated to five sessions of rTMS-sham, and
after a two-week washout period will be reallocated to
five sessions of rTMS-active). The two-week washout
period has been used in some studies [24, 27] and was
shown to be enough to reset the effects of the first five
sessions, considering that the motor effects of the rTMS
in individuals with iSCI are sustained for 1 h [24] to two
weeks [14] and that spasticity effects endure for one
week [16, 23]. Figure 1 summarizes the planned experi-
mental design. This research protocol follows the
SPIRIT recommendations. For the SPIRIT Checklist see
Additional file 1 and for the SPIRIT Figure see Fig. 2.
Table 1 provides an overview of the trial characteristics,
based on the WHO Trial Registration Data Set.
Participants and sampling
Participants will be recruited through referral by medical
practitioners or therapists who work at the Physiother-
apy Health Center of Paraíba State University in Brazil
in single-stage cluster sampling. Those interested in par-
ticipating will undergo a detailed screening against the
eligibility criteria for enrollment in the study.
Inclusion criteria
Participants will be included if they have agreed to partici-
pate in the study and have signed an informed consent
form. They will have a clinical diagnosis of iSCI with non-
progressive etiology which is characterized by spinal, vas-
cular, and infectious trauma. Neuroimaging examinations,
such as computed tomography and nuclear magnetic res-
onance imaging, will be used to exclude SCIs due to pro-
gressive worsening conditions such as neurodegenerative,
tumor, and demyelinating pathologies [28, 29]. The partic-
ipants should be at least six months post iSCI, clinically
stable, aged 18–60 years, have a satisfactory score in Scale
of Mini-Mental State Examination (MMSE) (i.e. cut-off
points of 13 for illiterates, 18 for low and middle school,
Fig. 1 Flowchart for the rTMS study protocol. The participants will be
selected and the eligibility assessment will be applied. They will then
be randomized and allocated to group 1 (starting with rTMS-active)
or group 2 (starting with rTMS-sham). Five sessions of rTMS-active
and sham will be applied to participants in each group over one
week, with a washout period (two weeks). Assessments will be
before and after each intervention period (i.e. sham and active)
using the motor and sensory scales, spasticity scale, and
surface electromyography
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and 26 for high school), have no pathological alterations
on electroencephalography (EEG), be clear of depression
as assessed by the Hamilton Depression Scale (HAM-D),
and be currently receiving conventional sensorimotor
physiotherapy, to a maximum of three times per week.
Exclusion criteria
Participants will be excluded if they have a metal pros-
thesis in some part of the body, use a cardiac pacemaker,
have either cognitive impairment, psychotic, or schizo-
phrenic disorders as diagnosed by the rehabilitation
team, neuropsychiatric co-morbidity, or use drugs that
reduce either seizure threshold or spasticity. Individuals
participating in intensive programs of rehabilitation that
could bias the results will also be excluded.
EG before the rTMS procedure will identify possible
brain bioelectrical abnormalities (such as interictal epi-
leptiform discharge, generalized photosensitivity, burst
suppression, hypsarrhythmia) that could be related to
the possibility of epileptic discharges [30, 31], thus
reducing the risk of seizures during rTMS, since the
high-frequency stimulation might lead to cortical hyper-
activity. If any of these abnormalities are identified, the
individual will be excluded.
Dropout criteria
Participants will be withdrawn from the study if they are
not willing to continue their participation, cannot be
present on the day of the experiment or miss a treat-
ment section, and/or change their form of rehabilitation
during the study.
Randomization
Participants will be randomly allocated to either group 1
(rTMS-active) or group 2 (rTMS-sham) with a 1:1 allo-
cation defined by a computer-generated randomization
using the R package (R Foundation for Statistical
Computing) [32]. Randomization will be under the con-
trol of a blinded investigator who will be the only person
allowed to manage the electronic security file of the
randomization to assign the individuals. The investigator
will be blind to the group in which the participant is
allocated to.
Blinding
The participants, researchers, and outcome assessors
will remain blind to group allocation during the study.
To ensure proper blinding, participants will receive
Fig. 2 SPIRIT figure. Description of the rTMS study protocol
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codes and will be concealed from the allocation process
by one different researcher. The researchers responsible
for applying the intervention and the outcome assessors
will not know the study design, allocation, objectives,
and expected outcomes.
In addition, for the blinding of the experimenter
(responsible for applying the intervention), one assessor
(responsible for randomization) will be in charge of
giving the active or sham coil to the experimenter. The
sham coil has exactly the same shape of the active coil.
Further details are presented in the “rTMS-sham”
section.
Allocation concealment
Allocation concealment will successfully be reached
since no one involved in this study (i.e. the participants,
researchers, and outcome assessors) will be aware of the
treatment allocations. Furthermore, investigators will
have no control over the order of patients randomized.
A blinded investigator will encode the individuals and
groups of intervention. To perform the allocation pro-
cedure, the encoded groups will be placed inside a
closed opaque envelope, which will be labeled with the
code for each participant. Envelopes will be opened only
during the time of active or sham intervention.
Table 1 Trial characteristics based on WHO Trial Registration Data Set
Data category Trial information
Primary registry and trial
identifying number
ClinicalTrials.gov, ID: NCT02899637
Date of registration in
primary registry
25 August 2016 on
Secondary identifying
numbers
Ethical Committee of Paraiba State University, under the number CAEE: 18753713.0.0000.5187
Source(s) of monetary or
material support
Foundation of Support for Research of São Paulo
State - FAPESP #2015/13096-1 and Coordination for Higher Education Staff Development - CAPES.
Primary sponsor University of Sao Paulo – USP
Secondary sponsor(s) NA
Contact for public
queries
FHM, AVLA
Contact for scientific
queries
FHM, AVLA
Public title Effects of transcranial magnetic stimulation on incomplete spinal cord injury
Scientific title Effects of high-frequency transcranial magnetic stimulation on functional performance in individuals with incomplete spinal cord
injury: study protocol for a randomized controlled trial
Country of recruitment Brazil
Health condition(s) or
problem(s) studied
Spinal cord injury
Interventions High-frequency repetitive transcranial magnetic stimulation on the lower-limb area of the motor cortex, over one week
(five consecutive sessions – once a day)
Key inclusion and
exclusion criteria
Inclusion criteria: clinical diagnosis of iSCI with non-progressive etiology; at least six months post iSCI; clinical stability; age
range 18–60 years; satisfactory score in Scale of Mini-Mental State Examination (i.e. cut-off points of 13 for illiterates, 18 for low
and middle school, and 26 for high school); no pathological alterations on electroencephalography; absence of depression
as assessed by the Hamilton Depression Scale and receive sensorimotor conventional physiotherapy. Exclusion criteria: metal
prosthesis in some part of the body; cardiac pacemaker; either cognitive impairment, psychotic, or either schizophrenic
disorders; neuropsychiatric co-morbidity; drugs that reduce seizure threshold or spasticity
Study type Interventional allocation: randomized
Masking: double-blind
Assignment: crossover
Primary purpose: treatment
Date of first enrolment December 2017
Target sample size 20
Recruitment status Recruiting
Primary outcome(s) Change in motor scores from baseline to four weeks
Key secondary
outcome(s)
Assessment of change in sensory and spasticity scores from baseline to four weeks
NA not available
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Intervention
All participants will attend the assigned rTMS interven-
tion as follows: there will be ten sessions over two
weeks, in which five sessions will be active and five will
be sham, separated by a two-week washout period. The
sessions will be administered consecutively and once a
day. The researchers will be trained to perform both
rTMS-sham and rTMS-active interventions.
rTMS-active
Over five consecutive sessions per week (i.e. one session
daily), rTMS-active will be performed with a frequency
of 5 Hz and 12 pulse trains. The stimulation intensity
will be set at 100% of the motor threshold of the area
corresponding to the abductor pollicis brevis. The stimu-
lation target will be the area associated with the bilateral
lower-limb motor area (i.e. vertex, Cz) of the M1.
We chose an intensity of 100%, based upon the limita-
tions reported by Kumru et al. [16], who showed that an
intensity of 90% applied during active rTMS was relatively
low for leg muscles. In this line of reasoning, Rossini et al.
[17] suggests that stronger descending excitatory drive
shall be obtained by higher stimulus intensities, thereby
yielding a faster temporal-spatial summation on cortico-
motoneuron connections. We have also taken into consid-
eration that some studies suggest the use of even higher
intensities (some used 110–120% in individuals with
Parkinson’s disease, for example) considering the elevated
motor threshold of lower-limb muscles [33, 34]. The
intensity of 100% was then chosen according the safety
criteria suggested by Rossi et al. [9].
rTMS-sham
The rTMS-sham will be performed over five consecutive
sessions per week (one session daily.) The sham coil will
be used because it ensures the attenuation of the mag-
netic field while appearing to be the same shape as the
active coil, with good approximation of auditory feed-
back [35]. In addition, the tactile contact of the coil with
the skull is maintained.
Procedures
The participants will be positioned comfortably in either
a normal chair or a wheelchair, depending on the level
of motor commitment of each patient. The feet will be
positioned flat on the floor and the hands will rest on
the thigh, in the supine position.
The rTMS stimulator will be connected to a figure-
eight coil (i.e. butterfly coil) and positioned on the vertex
of the lower-limb motor area, which corresponds to the
apical surface of the skull. We chose to stimulate the
vertex point because the motor impairment of subjects
with iSCI occurs bilaterally, although the degree of in-
volvement varies from one side to the other. Therefore,
both cortical sides will be stimulated simultaneously, as
the vertex point is equidistant between the left and right
hemispheres [36, 37]. Standardized caps will be used, in
accordance with the International 10-20 system EEG.
Such a procedure will be used to find the motor thresh-
old, a point which corresponds to the motor area of the
abductor pollicis brevis, and so marks the point corre-
sponding to the vertex.
rTMS protocol
Magnetic stimulator
The rTMS will be applied using Neurosoft - Neuro-MS 5
(Neurosoft Ltd®, Ivanovo, Russia), a commercially avail-
able transcranial magnetic stimulator equipped with an
angulated figure-eight-shaped coil (AFEC – 01-100).
Target
rTMS will be applied to an angulated figure-eight coil
over the lower-limb motor area localized in M1 (in order
to stimulate both lower limbs), with the handle of the
coil parallel to the interhemispheric midline (pointing
occipitally) as used by Khedr et al. [33], Jetté et al. [38],
and Ji et al. [39] based on the vertex position of the
International 10-20 system EEG.
When the orientation of the handle of a figure-eight
coil is parallel to the interhemispheric midline (poster-
ior–anterior direction), there is a TMS motor cortex ac-
tivation through the preferential recruitment of cortical
interneurons and through activating the pyramidal tract
indirectly [17, 34, 40, 41]. Thus, the biological effect
depends on the neuronal circuit finally recruited [17].
rTMS sessions
Each session will be held at the Neuromodulation
Laboratory of UEPB, using the same equipment during
the same time of day. Each session will consist of 12
trains of 50 magnetic pulses at 5 Hz on each train. These
pulses will be separated by 10-s intervals between each
train. Intensity will be set at 100% of the individual’s
RMT, defined as the lowest stimulation intensity that,
within ten trials, induced at least five motor-evoked po-
tentials assessed on the first dorsal interosseous muscle
in the resting state. The parameters of rTMS were
chosen based on safety parameters of the both National
Institute of Neurological Disorders and Stroke (NINDS)
and the paper by Rossi et al. [9].
Primary outcomes
To evaluate the motor and sensory effects of the high-
frequency rTMS in the lower-limb motor area on M1
(i.e. vertex, Cz) and check the possibility of generating
motor gains in participants with iSCI, we will observe
the change from baseline motor values provided by the
ASIA score.
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Only one researcher will be responsible for evaluating
all of the participants through both the sensorimotor
scales and electromyography (EMG). This researcher
will be a physiotherapist who will also receive training to
use the scales and EMG device. In addition, we will per-
form an evaluation of the intra-rater reliability of the
instruments used in this study. Adverse events will be
collected using a form for adverse events at each assess-
ment point and any adverse event related to the inter-
vention will be reported.
ASIA – motor score
The International Standards for Neurological Classification
of Spinal Cord Injury (ISNCSI) is a medical examination
from which part of the ASIA motor score is derived [42].
It uses a test of the strength of ten key muscles on each
side of the body (e.g. elbow flexors, wrist extensors, hip
flexors, quadriceps, dorsi flexors). The score ranges from 0
(no contraction) to 5 (normal resistance) through a full
range of motion. A total possible score of 50 for the upper
extremities (UE) and 50 for the lower extremities (LE) may
be obtained [42].
Secondary outcomes
ASIA – sensory score
The ASIA sensory score is also part of the assessment for
the ISNCSI [42]. The test involves pinprick and light touch
sensation at key points representing each dermatome of
the body, scored on a three-point scale (0, 1, and 2). Scores
will be summed to give a total possible score of 224, where
a higher score indicates better sensation than a lower
score [42].
Fugl–Meyer scale for upper and lower members (motor part
- FMS)
The FMS is an instrument used to evaluate body func-
tion impairment after stroke [43]. This scale assesses five
domains: motor; sensory; balance; range of motion; and
joint pain [43]. The UE (i.e. shoulder, elbow, forearm,
wrist, and hand) and LE (i.e. hip, knee, and ankle) are
assessed within the motor domain, then impairment se-
verity and functional ability are indexed [44]. Sullivan
et al. [44] affirm that it is likely that the FMS motor
score may be a clinical measure indicative of white mat-
ter damage within CST fibers. This potential can justify
its use in SCI populations. This scale is a 226-point
multi-item Likert-type scale used to measure recovery.
Multiple items are scored on a three-point ordinal scale
(0 = cannot perform, 1 = perform partially, 2 = performs
fully) [43]. In addition, the motor domain includes score
ranges from 0 (plegia) to a maximum of 100 (normal
motor performance); 66 points can be divided for the
UE and 34 points for the LE [44, 45]. In this study we
will only use the motor domain and evaluation will take
place bilaterally.
Surface electromyography (EMG)
The EMG will be recorded differentially using round-
shaped surface electrodes (Ag-AgCl, 0.8 cm diameter, with
an inter-electrode distance of 2 cm) over the following
muscles: vastus medialis; vastus lateralis; rectus femoris;
biceps femoris; gastrocnemius; and tibialis anterior. We
will position the electrodes at standard Surface
ElectroMyoGraphy for the Non-Invasive Assessment of
Muscles (SENIAM) positions [46], and a ground electrode
will be over the tibia of the left leg. The EMG signals will
be amplified and filtered (5 Hz to 2 kHz) by a biological
data acquisition system Miotool 400 (Miotec®, Brazil) and
sent to an A/D interface (National Instruments, Austin,
TX, USA) with a 2-kHz sampling rate. Data will be stored
on hard disk for later off-line processing. Data will be
collected using the software Miograph (Miotec®). The
EMG acquisitions will be obtained during knee extension,
knee flexion, plantar flexion, and dorsiflexion. For 1 min,
participants will perform contractile movements with
speed controlled by audible and visual signals. The
normalization procedure for peak contraction will be
made to standardize EMG acquisitions and make them
comparable.
Modified Ashworth Scale (MAS)
The MAS is an instrument used to evaluate the spasticity
(i.e. grading the resistance encountered during such
passive muscle stretching) [47, 48]. The grades of spasti-
city are 0 (normal muscle tone), 1 (slight increase in
muscle tone, when move a limb), 2 (more marked increase
in muscle tone, but limb easily flexed), 3 (considerable
increase in muscle tone), and 4 (limb rigid in flexion or
extension) [47].
Socio-demographic questionnaire (SDQ)
The SDQ will be used to collect personal, socio-
environmental, and clinical information. It will also
determine information used to evaluate participants’ eli-
gibility criteria. Our research center standardized this
qualitative instrument, but a pilot test will be conducted
to identify possible necessary adjustments to this ques-
tionnaire. In summary, this scale will be used as a sam-
ple description and as an eligibility criterion.
Scale of Mini-Mental State Examination
The MMSE assesses the mental state of the individuals
assessed [49, 50]. The maximum score is 30 and there
are two domains. The first tests for vocal responses,
which covers orientation, memory, and attention
(maximum of 21 points). The second tests for the ability
to name objects, obey verbal and written commands,
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write a sentence spontaneously, and copy a complex
polygon (maximum of nine points) [50, 51]. In Brazil,
Bertolucci et al. [52] translated the MMSE. They found
that the educational level of participants influenced their
total score on the MMSE. As a result, the authors have
proposed different cut-offs for the diagnosis of cognitive
decline. The suggested cutoff points were 13 for illiter-
ates, 18 for low and middle school, and 26 for high
school. We will use this scale as an eligibility criterion.
Hamilton Rating Scale for Depression
The HAM-D is used to identify depression and contains
17 items plus four additional variables (diurnal variation,
derealization, paranoid symptoms, and obsessive symp-
toms) [53]. Hamilton has not established a cut-off point,
but in clinical practice scores higher than 25 points
characterize severely depressed patients; scores in the
range of 18–24 indicate moderate depression; and scores
in the range of 7–17 indicate mild depression [54]. We
will use this scale as an eligibility criterion.
Electroencephalogram
EEG provides a measurement of brain electrical activity
(i.e. the amount of synaptic activity synchronized) re-
corded from scalp electrodes [55]. Applications of EEG
can be used in identification of nature, type, and severity
of epileptiform activity [56]. In this study, the EEG will
be used to identify individuals with epilepsy or brain-
activity patterns that may indicate possible underlying
seizures. Therefore, this exam will serve only as an eligi-
bility criterion.
Neurological examination (NE)
Clinical data collection will be achieved via qualitative
standardized NE. This instrument consists of four parts:
a history of the lesion and clinical symptoms; sensory
and motor evaluation; functional activities; superficial
and deep reflections.
Statistical analysis
Sample size
The sample size was calculated using statistical soft-
ware (GPower 3.1.5) [57] on the main outcome meas-
ure (i.e. the motor score). This calculation was based
on data from one study with a group of SCI individuals
that received high-frequency rTMS at a frequency of
5 Hz on the vertex, which related to an improvement
in clinical measures of the motor score [24]. The power
was 0.80; the alpha was 0.05, the effect size was 0.65
(Cohen’s d). The sample estimation indicated that 14
participants would be necessary (i.e. seven per group).
With an adjustment to allow for a dropout rate, we will
recruit 20 participants.
Data analysis
The analysis will follow a pre-specified analysis plan, based
on comparing the groups as randomized (intention-to-
treat). All data will be presented as mean ± standard
deviation and summarized in frequency tables. We will
use Microsoft Office Excel for Windows (version 2013) to
store the data and the Statistical Package for Social
Sciences (SPSS-IBM®) version 21 for Windows to perform
statistical analysis. The normality and homogeneity of all
variables (i.e. primary and secondary outcomes) will be
tested with the Shapiro–Wilk and Levene’s test, respect-
ively. For non-parametric data, the Friedman test will be
used followed by the Wilcoxon post hoc test. We will use
the ANOVA two-way (2 × 4) for the inferential statistic of
the parametric data, with Tukey’s post hoc tests.
Significance level will be set as α ≤ 0.05 and the effect size
will be calculated by eta-squared (ŋ2).
Expected risks
High-frequency rTMS is a safe non-invasive technique
according to current knowledge [9, 58]. Some studies in-
dicate that there may be weak tension headaches and
muscle spasms experienced during rTMS [59]. Overall,
in cases where contraindications or safety parameters
were not maintained, serious adverse events such as sei-
zures occurred [9]. According to Rossi et al. [9], a large
number of individuals were subjected to studies with
rTMS since 1998 (when the limit parameters by Wasser-
mann et al. [58] were defined) and a small number of
seizures were observed. Therefore, the risk of rTMS-
induced seizures is considered very low. To avoid ad-
verse effects and risks to the individual, the rTMS
parameters used in the present trial will be within the
safety limits set by the NINDS and by Rossi et al. [9],
which were updated security settings for transcranial
magnetic stimulation.
Expected benefits
Intervention with high-frequency rTMS over the param-
eters established in this study may generate motor gains
and consequent functional recovery in patients with
iSCI. Motor gains and functional recovery might con-
tribute to an improved quality of life and functional
independence. Moreover, the participation of those in
this study will contribute towards the construction of
scientific knowledge on the use of rTMS in iSCI.
Discussion
Individuals with iSCI show clinical symptoms which are
associated with reduced quality of life and functional
independence [60, 61]. The CNS may be able to recover
naturally after injury due to plasticity mechanisms and
reorganization of residual neural pathways [5]. However,
natural recovery is limited and cannot be relied upon
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[6]. It is therefore plausible that stimulation as a re-
habilitation technique may be crucial in enhancing CNS
plasticity. High-frequency rTMS has emerged as a prom-
ising technique in stimulating neural reorganization and
synaptic plasticity in cortical and subcortical networks,
thereby affecting the descending control of spinal excit-
ability [11, 12, 14, 34, 62, 63]. These mechanisms might
accelerate the development of neural connectivity respon-
sible for motor function improvement [12, 14, 22, 24, 63].
Although an adaptive reorganization involves the for-
mation of new connections and restoration of pre-
existing connections, studies that directly address
quantitative parameters associated with neuronal repair
are limited. This is because most of the outcome mea-
sures are not able to assess the neurophysiological
substrates that directly contribute to functional recovery,
such as specific mechanisms within the brain and spinal
cord that influence the generation of the motor com-
mand to the affected limbs [63].
The protocol described herein is expected to be the
first fully randomized controlled double-blind crossover
trial to assess the effect sizes associated with rTMS
intervention in participants with iSCI. We expect the
outcomes of the present study to provide additional clin-
ical evidence of the potential benefits of high-frequency
rTMS applied to the lower-limb motor area to improve
sensorimotor recovery and/or to reduce spasticity in pa-
tients with iSCI.
Trial status
Participant recruitment started in May 2017 and is ex-
pected to end in November 2017. Study completion is es-
timated by May 2018.
Additional file
Additional file 1: SPIRIT 2013 Checklist. rTMS study protocol. (DOC 122 kb)
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